Clinical Trial Update: A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update on AK104 plus axitinib in advanced/metastatic special pathological subtypes of renal cell carcinoma (Phase 1/Phase 2), currently active …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma
• Sarcomatoid Renal Cell Carcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• Axitinib (Axitinib)

Snippet

Sponsor: Hao Zeng | Conditions: Renal Cell Carcinoma, First-line Treatment | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING